# A selected reference list for aspirin and cancer Q&A on aspree.org

## Why is ASPREE and ASPREE-XT looking at cancer outcomes?

### Meta-analyses published in The Lancet by other researchers such as Rothwell *et al*. provided evidence in support of low dose aspirin preventing cancers of the colon, oesophagus, lung and stomach.

Reference list:


1. Rothwell PM, Fowkes GR, Belch JFF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials, *The Lancet*, Volume 377, Issue 9759, 1–7 January 2011, Pages 31-41, ISSN 0140-6736, 10.1016/S0140-6736(10)62110-1.
2. Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, Manson JE, Hennekens CH, Buring JE. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. *JAMA.* 2005;294:47–55
3. The Steering Committee of the Physicians' Health Study Research Group. Findings from the aspirin component of the ongoing Physicians' Health Study. *N Engl J Med*. 1988;318:262-264.
4. Rothwell PM, Price FP, Fowkes FGR, Zanchetti A, Roncaglioni MC, Tognoni G, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. The Lancet 2012; 379: 602-12.
5. Rothwell PM, Wilson M, Price JFF, Belch JF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. *The Lancet.* 28 April 2012 (Volume 379 Issue 9826 Pages 1591-1601 DOI: 10.1016/S0140-6736(12)60209-8)
6. Serebriiskii IG, Connelly C, Frampton G. *et al.* Comprehensive characterization of *RAS* mutations in colon and rectal cancers in old and young patients. *Nat Commun* 10, 3722 (2019). https://doi.org/10.1038/s41467-019-11530-0
7. Wang M-X, Ren J-T, Tang L-Y, Ren Z-F. Molecular features in young vs elderly breast cancer patients and the impacts on survival disparities by age at diagnosis. *Cancer Med*. 2018; 7: 3269– 3277. https://doi.org/10.1002/cam4.1544
8. Seshasai SRK, Wijesuriya S, Sivakumaran R, Nethercott S, Erqou S, Sattar N, et al. Effect of aspirin on vascular and nonvascular outcomes meta-analysis of randomized controlled trials. *Arch Intern Med.* 2012;172(3):209-216. doi:10.1001/archinternmed.2011.628
9. McNeil JJ*, Nelson MR*, Woods RL, Lockery JE, Wolfe R, Reid CM, Kirpach B, Shah RC, Ives DG, Storey E, Ryan J, Tonkin AM, Newman AB, Williamson JD, Margolis KL, Ernst ME, Abhayaratna WP, Stocks N, Fitzgerald SM, Orchard SG, Trevaks RE, Beilin LJ, Donnan GA, Gibbs P, Johnston CI, Radziszewska B, Grimm R & Murray AM, on behalf of the ASPREE Investigator Group (* joint first authors). Effect of aspirin on all-cause mortality in the healthy elderly. New England Journal of Medicine, 2018, 379:1499-1508. doi: 10.1056/NEJMoa1803955
10. McNeil JJ, Gibbs P, Orchard SG, Lockery JE, Bernstein WB, Cao Y, Ford L, Haydon A, Kirpach B, Macrae F, McLean C, Millar J, Murray AM, Nelson MR, Polekhina G, Reid CM, Richmond E, Rodríguez LM, Shah RC, Tie J, Umar A, van Londen GJ, Ronaldson K, Wolfe R, Woods RL, Zalcberg J, Chan A, for the ASPREE investigator Group. Effect of aspirin on cancer incidence and mortality in older adults. JNCI: Journal of the National Cancer Institute, djaa114, doi.org/10.1093/jnci/djaa114
11. McNeil JJ, Aspirin and primary prevention of colorectal cancer: a still evolving story, JNCI: Journal of the National Cancer Institute, 2021;djab010, doi.org/10.1093/jnci/djab010